At the sharp end

Article

Hoya Surgical Products now has, what it claims to be, the Sharpest Edge on the market. The yellow aspheric blue-light filter IOLS iSymm has undergone a unique manufacturing process which makes it the sharpest of all commercially available IOLs currently in the market.

Hoya Surgical Products now has, what it claims to be, the Sharpest Edge on the market. The yellow aspheric blue-light filter IOLS iSymm has undergone a unique manufacturing process which makes it the sharpest of all commercially available IOLs currently in the market.

Professors Liliana Werner and Manfred Tetz have been studying the edge profiles of currently available IOLs and their recent improvements and their research is to be published in the European Opthalmic Review (Vol 3 Issue 2). Its conclusions are that their analysis revealed “a large variation of deviation from a perfect square, as well as mean values that were higher for hydrophilic acrylic lenses in comparison with values reported for hydrophobic acrylic and silicone lenses. Only existing and future clinical data will help us better understand the effect of microedge structure and design on reducing posterior capsule opacification (PCO), but perhaps a cut-off value to clinically label an IOL as square-edged should be sought. The methodology used in such studies can help optimise the edge profile of IOLS.”

Another positive announcement from the company is that HOYA received the FDA Approval for the iSert preloaded implantation system in the USA. “This big step allows HOYA Surgical Optics now to introduce the first and only preloaded intraocular lens injection system in the US,” said Hoya's head of marketing, Mike Galloway.

Galloway also confirmed that HOYA Surgical Optics will provide ophthalmologists with advanced products and professional services with plenty of ideas in the pipeline.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.